Patent · US Active

Bispecific T cell activating antigen binding molecules

US10766967B2 · kind B2 · utility

0Cited by

30References

50Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Marina BACAC · Schlieren, CH
Tanja Fauti · Zürich, CH
Sabine Imhof-Jung · Planegg, DE
Christian Klein · Iffeldorf, DE
Stefan Klostermann · Schwanau, DE
Ekkehard Moessner · Kreuzlingen, CH
Michael Molhoj · Munich, DE
Christiane Neumann · Niederweningen, CH
Joerg Thomas Regula · Munich, DE
Wolfgang Schaefer · Sankt Augustin, DE
Pablo Umana · Wollerau, CH

Key dates

Filing date	Sep 30, 2016
Grant date	Sep 8, 2020
Priority date	—
Expiry date	Sep 30, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.